EN
Instrument Fundamentals
| Date | Close | Change | Change (%) | Open | High | Low |
|---|
News
BioNTech, Bristol Myers' Pumitamig Shows 36.7% Response Rate In Phase 2 NSCLC Trial
Citizens Financial Group Inc. RI Buys 44,768 Shares of Bristol Myers Squibb Company $BMY
Tempus AI's (TEM) Buy Rating Reiterated at Needham & Company LLC - Zolmax
Bristol Myers Squibb Company $BMY Stake Lessened by Lantern Wealth Advisors LLC - Zolmax
Bristol Myers Squibb Company $BMY Stock Position Decreased by Lantern Wealth Advisors LLC - Markets Daily
Bristol Myers Squibb Company $BMY Shares Acquired by Brookstone Capital Management
The Call Bristol-Myers Squibb Bulls Got Right
Bristol Myers Squibb Reports Patient Death in MS CAR-T Therapy Trial, ETPharma
31,873 Tempus AI, Inc. $TEM Shares Acquired by Washington Trust Advisors Inc.
Bristol Myers Squibb (NYSE:BMY) Cut to "Hold" at Zacks Research
Bristol Myers Squibb (NYSE:BMY) Downgraded by Zacks Research to Hold - Stock Observer
Tempus AI, Inc. $TEM Shares Bought by Washington Trust Advisors Inc. - Stock Observer
Bristol Myers Squibb (NYSE:BMY) & Astellas Pharma (OTCMKTS:ALPMY) Financial Analysis - Daily Political
Neoadjuvant nivolumab with or without visugromab in muscle-invasive bladder cancer: the phase 2a GDFATHER-NEO trial
Tempus AI (NASDAQ:TEM) Stock Rating Reaffirmed as Buy by Needham & Company LLC - Markets Daily
Tempus AI's (TEM) "Buy" Rating Reiterated at Needham & Company LLC - Markets Daily
Bristol Myers Squibb Moves On Two Fronts: MS Cell Therapy Data And Tempus AI Expansion; Stock Down
Bristol Myers Squibb Reports CAR T-Cell Therapy Data In Multiple Sclerosis
Fifth edition of MCADDI 2026 to be held at University of Hyderabad from October 25
Tempus AI Expands Bristol Myers Partnership With Multi-Year Oncology, AI Data Deals | Morningstar
Bristol Myers Squibb Presents Results from Phase 1 Breakfree-2 Study of Zolacabtagene Autoleucel (BMS-986353) in Patients with Highly Active Relapsing and Progressive Forms of Multiple Sclerosis at MSToronto 2026 | Morningstar
Tempus AI (NASDAQ:TEM) Stock Rating Reaffirmed as "Buy" by Needham & Company LLC - Stock Observer
Tempus AI (NASDAQ:TEM) Earns Buy Rating from Needham & Company LLC - Stock Observer
Tempus AI (NASDAQ:TEM) Given "Buy" Rating at Needham & Company LLC - Stock Observer
Tempus AI's (TEM) "Buy" Rating Reaffirmed at Needham & Company LLC - Stock Observer
Tempus AI's (TEM) Buy Rating Reiterated at Needham & Company LLC - Stock Observer
Tempus AI (NASDAQ:TEM) Stock Keeps Buy Rating at Needham & Company LLC - Stock Observer
Pathos AI teams up with Bristol Myers and Tempus AI to advance drug development
Pathos AI Announces Strategic Collaborations with Bristol Myers Squibb and Tempus AI to Advance AI-Driven Drug Development Beginning with Alzheimer's Disease and Other Neurological Conditions | Morningstar
3 Defensive Stocks to Buy as the AI Selloff Rattles Wall Street
NBT Bank N.A. Buys 52,930 Shares of Bristol Myers Squibb Company $BMY
What is Erste Group Bank's Estimate for BMY FY2027 Earnings? - Stock Observer
Bispecific dual T cell agonist invikafusp alfa in solid tumors: the phase 1/2 START-001 trial
Lymph node-targeted, mKRAS-specific amphiphile vaccine in pancreatic cancer: the randomized phase 2 AMPLIFY-7P trial
Why Bristol-Myers Squibb (BMY) Is Back In The Spotlight
BioNTech Advances Phase 3 Clinical Trial of Pumitamig in Combination with Gilead's TROP2-Directed ADC Sacituzumab Govitecan in Triple-Negative Breast Cancer | Morningstar
Amgen Inc. $AMGN Shares Sold by Foster Victor Wealth Advisors LLC
Astellas Pharma (OTCMKTS:ALPMY) versus Bristol Myers Squibb (NYSE:BMY) Financial Analysis - Zolmax
Bristol Myers Squibb (BMY) Expected to Release Earnings on Thursday
Ovarian Cancer Pipeline 2026: Emerging Drugs, Regulatory Milestones, and Strategic Moves by Leading Players | Pfizer, Daiichi Sankyo, Astellas Pharma, Jiangsu HengRui, Boehringer Ingelheim, Impact | ABNewswire
Bristol Myers Squibb Company $BMY Shares Sold by SteelPeak Wealth LLC
RBC Capital Reaffirms Their Hold Rating on Sanofi (SNYNF)
RBC Capital Remains a Buy on Eli Lilly & Co (LLY)
Bristol Myers Squibb Company $BMY Stock Sold by Robeco Institutional Asset Management B.V. - Daily Political
Sumitomo Mitsui DS Asset Management Company Ltd Sells 21,624 Shares of Bristol Myers Squibb Company $BMY - Daily Political
NATCO launches Chemo drug in US
Moderna Jumps 7% While Melanoma Vaccine Data Looms; Bristol Myers Squibb Rises 5%, Pfizer Advances 2%
Bristol Myers (BMY) Has New Cancer Wins. Can They Offset the Patent Cliff?
Bristol Myers Squibb Company (NYSE:BMY) Stock Has Average Target Price of $64.88 According to Analysts
Analysts' Recent Ratings Updates for Bristol Myers Squibb (BMY) - Stock Observer
Bristol Myers Squibb Company $BMY Stock: Assenagon Asset Management S.A. Raises Position
RBC Capital Sticks to Its Hold Rating for GlaxoSmithKline (GSK)
AbbVie (ABBV) Receives a Buy from RBC Capital
Bristol Myers Squibb (BMY) Heads To ESMO 2026 With New Oncology Data
Drugmakers seek to intervene in lawsuit challenging 340B pilot
AbbVie vs. Bristol Myers: Is AbbVie's Valuation Premium Worth Paying?
Microsoft 365 Copilot vs Google Gemini Enterprise: 2026 Adoption, Productivity Gains and Real-World AI Deployments
Bristol Myers is Cheaper Than Pfizer, but Its 40% Earnings Jump Has a Catch
Bristol Myers vs. Eli Lilly: Is BMY's Deep Valuation Discount Hiding an Opportunity?
Analyzing Milestone Pharmaceuticals (NASDAQ:MIST) and Bristol Myers Squibb (NYSE:BMY) - Zolmax
Rare prostate cancer histologies: detection, characteristics and treatment
USA Financial Formulas Makes New $919,000 Investment in Bristol Myers Squibb Company $BMY - Markets Daily
13,923 Shares in Bristol Myers Squibb Company $BMY Bought by USA Financial Formulas - Zolmax
Lupin Receives CDSCO Approval for Nivolumab Biosimilar in India, ETPharma
Birch Hill Investment Advisors LLC Acquires 160,411 Shares of Bristol Myers Squibb Company $BMY
Bristol Myers Squibb Company $BMY Shares Newly Purchased by New England Research & Management Inc.
Bristol Myers Squibb (NYSE:BMY) Stock Moved Up to "Strong-Buy" by The Goldman Sachs Group
Bristol Myers Squibb Company $BMY Stock Bought by Howard Capital Management LLC - Daily Political
Analysts Conflicted on These Healthcare Names: Perspective Therapeutics (CATX), Bristol-Myers Squibb (BMY) and Incyte (INCY)
RBC Capital Sticks to Its Buy Rating for Roche Holding AG (RHHVF)
Eli Lilly & Co (LLY) Receives a Buy from RBC Capital
RBC Capital Sticks to Their Hold Rating for Merck & Company (MRK)
RBC Capital Reaffirms Their Hold Rating on Pfizer (PFE)
Bristol Myers Squibb's 4.2% Dividend Yield Comes With a Trade-Off Investors Should Know
Bristol Myers Squibb's Rally Has Momentum, but Can Its New Drugs Justify More Upside?
Triasima Portfolio Management inc. Purchases New Stake in Bristol Myers Squibb Company $BMY
Iams Wealth Management LLC Acquires 24,964 Shares of Bristol Myers Squibb Company $BMY
How Mixed Admilparant Results and Strong Oncology Data Will Impact Bristol Myers Squibb (BMY) Investors
Insitro's Virtual Human attracts $1.5B MASH deal with Astrazeneca
Bristol Myers Squibb Company $BMY Stock Sold by Chiron Capital Management LLC - Stock Observer
Bristol Myers Squibb Company $BMY Shares Sold by Viking Fund Management LLC
Bristol Myers Squibb Company $BMY Position Reduced by Fort Washington Investment Advisors Inc. OH
Head-To-Head Analysis: Milestone Pharmaceuticals (NASDAQ:MIST) & Bristol Myers Squibb (NYSE:BMY) - Markets Daily
65,007 Shares in Bristol Myers Squibb Company $BMY Purchased by B.A. Schrock Wealth Management Inc. - Stock Observer
14,607 Shares in Bristol Myers Squibb Company $BMY Acquired by Sanders Morris Harris LLC - Daily Political
Stock Market Movers: Best and Worst Performers of 14 October 2026
Bristol Myers Squibb (NYSE:BMY) Shares Up 4% - What's Next?
Bristol Myers Squibb Company $BMY Shares Sold by Perpetual Ltd
Bristol-Myers Squibb Company Stock Live Price, Chart, Analysis, News & Forecast - Buy, Sell & Trade US Equities Today
Personalized neoantigen-targeting cancer vaccines in ovarian cancer: a phase 1 trial
Talazoparib plus enzalutamide in high-volume metastatic hormone-naive prostate cancer: a randomized phase 2 trial
Renal Cancer Clinical Trial Pipeline Gains Momentum: 75+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight | ABNewswire
Bristol Myers Squibb Company $BMY Shares Sold by Courier Capital LLC - Zolmax
Bristol Myers Squibb (BMY) Stock Trades At A Discount Following Its 38% Run
BlackLine Honors Global Enterprise Leaders Transforming Financial Operations
Bristol Myers Squibb (BMY) Stock May Be Undervalued Despite Fresh Phase 3 Trial Wins
Bristol Myers Squibb (NYSE:BMY) Stock Price Target Cut by Wells Fargo & Company - Daily Political
BristolMyers News
CoreWeave Stock Forecast 2026–2030: Can CRWV Recover From the AI Debt Sell-Off?
Nebius Stock Price Prediction 2026–2030: Can AI Cloud Growth Justify the Cost?
Eli Lilly Stock Forecast 2026–2030: Can LLY Break Above $1,300 After Its 7% Five-Session Rally?
Is Tesla Stock a Good Buy Right Now? Earnings, AI Growth and Valuation Risks
Latest news
Show more
Microsoft Earnings Preview: Can Azure Growth Justify Rising AI Spending?
US Dollar Index Edges Lower Ahead of Fed Decision and Big Tech Earnings
Fed Rate Decision Preview: Will Kevin Warsh Hold Rates at 4% and Signal a December Hike?
Bitcoin Price Today Falls Below $80,000 as ETF Outflows and Liquidations Deepen the Sell-Off
Gold Price Forecast This Week: Can XAU/USD Reclaim $4,000 Before the Fed Decision?
